On October 31, 2023 EpimAb Biotherapeutics, a clinical stage biotechnology company specializing in the development of bispecific antibodies, reported that the company will present the first-in-human results for EMB-06 in a late-breaking poster presentation at the 2023 Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) Annual Meeting to be held in San Diego, California, from November 3-5 (Press release, EpimAb Biotherapeutics, OCT 31, 2023, View Source [SID1234636590]). This poster presentation will feature initial safety, efficacy, and pharmacokinetic/pharmacodynamic (PK/PD) data from the Phase I dose escalation study in relapsed or refractory multiple myeloma (NCT04735575; CTR20212633). The presentation details are as follows:
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Title: A Phase I Study of a Novel BCMA×CD3 Bispecific Antibody EMB06 in Relapsed or Refractory Multiple Myeloma
Abstract number: 1528
"We are very pleased to share the EMB-06 data as a late-breaker at the SITC (Free SITC Whitepaper) Annual Meeting. This data will provide the first clinical proof-of-concept that EpimAb’s differentiated bispecific platform and proprietary CD3 panel can be used to effectively target tumor associated antigens while lowering the risk of cytokine release and neurotoxicity," Dr. Chengbin Wu, Founder and CEO of EpimAb commented. "With multiple T cell engagers in our clinical and pre-clinical pipeline, EpimAb is looking forward to realizing the promising potential of this modality and to creating novel therapies for diseases with significant unmet need."
About EMB-06
EMB-06 is a novel 2+2 BCMA×CD3 T-cell engaging bispecific antibody discovered using EpimAb’s proprietary CD3 panel and bispecific platforms. Importantly, this molecule has demonstrated lower levels of cytokine release in preclinical and clinical studies. EMB-06 is currently being studied in a Phase I/II trial in relapsed or refractory multiple myeloma (NCT04735575; CTR20212633).